Literature DB >> 27929611

Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis.

Tom Bschor1,2,3, Hannah Kern4, Jonathan Henssler5, Christopher Baethge6.   

Abstract

OBJECTIVE: Nonresponders to antidepressant monotherapy during acute treatment of major depression are often switched to a new antidepressant. The objective of this meta-analysis was to compare the efficacy of switching to a new antidepressant with continuation of the first antidepressant. DATA SOURCES: PubMed, Embase, PsycINFO, and Cochrane Central Register of Controlled Trials (CENTRAL) databases and additional sources were systematically searched independently by 2 authors up to March 2015 without language limitations. With employment of a sensitivity-enhancing search strategy, generic terms for major depression, switching, and randomized trials were combined. STUDY SELECTION: Articles (3,234) were screened for trials of patients with major depression who had not responded to antidepressant monotherapy who were then randomized either to a new antidepressant or to continuation of the first antidepressant. Studies were subdivided into those not allowing for dose escalation in the continuation arm (strict analysis) and those allowing for dose escalation (broad analysis). DATA EXTRACTION: Data were extracted and risk of bias was assessed independently by 2 authors, and data were pooled using random effects models.
RESULTS: Four randomized controlled trials were included in the strict analysis and 8 in the broad analysis. In both analyses, switching was not superior to continuation: the standardized mean difference in the strict analysis was -0.17 (95% CI, -0.59 to 0.26; P = .45; I² = 77.8%) and in the broad analysis was 0.031 (95% CI, -0.26 to 0.32; P = .836; I² = 85.3%). All secondary outcome analyses (response and remission rates, low risk of bias studies only, leave-one-out analysis, dropouts) supported the results. There was no indication of publication bias.
CONCLUSIONS: There is a dearth of randomized controlled trials investigating switching. There is no high-level evidence that switching the antidepressant is effective when compared to simply continuing the initial antidepressant. Since there are better treatment options than switching, physicians should be cautious to switch antidepressants. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 27929611     DOI: 10.4088/JCP.16r10749

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse.

Authors:  Yuen-Siang Ang; Roselinde Kaiser; Thilo Deckersbach; Jorge Almeida; Mary L Phillips; Henry W Chase; Christian A Webb; Ramin Parsey; Maurizio Fava; Patrick McGrath; Myrna Weissman; Phil Adams; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Thomas Carmody; Gerard Bruder; Crystal M Cooper; Cherise R Chin Fatt; Madhukar H Trivedi; Diego A Pizzagalli
Journal:  Biol Psychiatry       Date:  2020-04-23       Impact factor: 13.382

2.  Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.

Authors:  Ole Köhler-Forsberg; Erik Roj Larsen; Henriette N Buttenschøn; Marcella Rietschel; Joanna Hauser; Daniel Souery; Wolfgang Maier; Anne Farmer; Peter McGuffin; Katherine J Aitchison; Rudolf Uher; Ole Mors
Journal:  Br J Psychiatry       Date:  2019-01-30       Impact factor: 9.319

Review 3.  A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression.

Authors:  Jenifer A Murphy; Jerome Sarris; Gerard J Byrne
Journal:  Depress Res Treat       Date:  2017-08-03

4.  Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study.

Authors:  Tempei Otsubo; Yoshinori Watanabe; Seiji Hongo; Mikichika Inoue; Kimiko Akimoto; Ken Murakami; Ryutaro Takahashi; Toshiaki Kikuchi
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-06       Impact factor: 2.570

5.  Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Authors:  M Dold; L Bartova; J Mendlewicz; D Souery; A Serretti; S Porcelli; J Zohar; S Montgomery; S Kasper
Journal:  Acta Psychiatr Scand       Date:  2018-02-28       Impact factor: 6.392

6.  SANRA-a scale for the quality assessment of narrative review articles.

Authors:  Christopher Baethge; Sandra Goldbeck-Wood; Stephan Mertens
Journal:  Res Integr Peer Rev       Date:  2019-03-26

7.  Predicting SSRI-Resistance: Clinical Features and tagSNPs Prediction Models Based on Support Vector Machine.

Authors:  Huijie Zhang; Xianglu Li; Jianyue Pang; Xiaofeng Zhao; Suxia Cao; Xinyou Wang; Xingbang Wang; Hengfen Li
Journal:  Front Psychiatry       Date:  2020-06-03       Impact factor: 4.157

8.  Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment.

Authors:  Yuri E Rybak; Ka S P Lai; Rajamannar Ramasubbu; Fidel Vila-Rodriguez; Daniel M Blumberger; Peter Chan; Nicholas Delva; Peter Giacobbe; Caroline Gosselin; Sidney H Kennedy; Hani Iskandar; Shane McInerney; Paula Ravitz; Verinder Sharma; Ari Zaretsky; Amer M Burhan
Journal:  Depress Anxiety       Date:  2021-02-02       Impact factor: 6.505

9.  Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.

Authors:  Tadashi Kato; Toshi A Furukawa; Akio Mantani; Ken'ichi Kurata; Hajime Kubouchi; Susumu Hirota; Hirotoshi Sato; Kazuyuki Sugishita; Bun Chino; Kahori Itoh; Yoshio Ikeda; Yoshihiro Shinagawa; Masaki Kondo; Yasumasa Okamoto; Hirokazu Fujita; Motomu Suga; Shingo Yasumoto; Naohisa Tsujino; Takeshi Inoue; Noboru Fujise; Tatsuo Akechi; Mitsuhiko Yamada; Shinji Shimodera; Norio Watanabe; Masatoshi Inagaki; Kazuhira Miki; Yusuke Ogawa; Nozomi Takeshima; Yu Hayasaka; Aran Tajika; Kiyomi Shinohara; Naohiro Yonemoto; Shiro Tanaka; Qi Zhou; Gordon H Guyatt
Journal:  BMC Med       Date:  2018-07-11       Impact factor: 8.775

10.  Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.

Authors:  Nadine Dreimüller; Stefanie Wagner; Alice Engel; Dieter F Braus; Sibylle C Roll; Stefan Elsner; André Tadić; Klaus Lieb
Journal:  BMC Psychiatry       Date:  2019-01-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.